COVID-19 associated candidemia: From a shift in fungal epidemiology to a rise in azole drug resistance
Medical Mycology · 2024
DOI: 10.1093/mmy/myae031 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Medical Mycology, 2024. Verfasst von Mohammad Javad Najafzadeh und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Parasitology and Mycology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. Hauptthemen laut MEDLINE: Candidemia, COVID-19. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: Elite Researcher Grant Committee, Mashhad University of Medical Sciences.
Abstract (Originalsprache)
Our understanding of fungal epidemiology and the burden of antifungal drug resistance in COVID-19-associated candidemia (CAC) patients is limited. Therefore, we conducted a retrospective multicenter study in Iran to explore clinical and microbiological profiles of CAC patients. Yeast isolated from blood, were identified by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry and subjected to antifungal susceptibility testing (AFST) using the broth microdilution method M27-A3 protocol. A total of 0.6% of the COVID-19 patients acquired CAC (43/6174). Fluconazole was the most widely used antifungal, and 37% of patients were not treated. Contrary to historic candidemia patients, Candida albicans and C. tropicalis were the most common species. In vitro resistance was high and only noted for azoles; 50%, 20%, and 13.6% of patients were infected with azole-non-susceptible (ANS) C. tropicalis, C. parapsilosis, and C. albicans isolates, respectively. ERG11 mutations conferring azole resistance were detected for C. parapsilosis isolates (Y132F), recovered from an azole-naïve patient. Our study revealed an unprecedented rise in ANS Candida isolates, including the first C. parapsilosis isolate carrying Y132F, among CAC patients in Iran, which potentially threatens the efficacy of fluconazole, the most widely used drug in our centers. Considering the high mortality rate and 37% of untreated CAC cases, our study underscores the importance of infection control strategies and antifungal stewardship to minimize the emergence of ANS Candida isolates during COVID-19.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Parasitology and Mycology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
- Allergy Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
- Lung Diseases Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
- Institute of Hygiene and Medical Microbiology, Medical University of Innsbruck, Innsbruck, Austria.
- Division of Mycology, Faculty of Medicine, Çukurova University, Adana, Türkiye.
ORCID-Profile: Mohammad Javad Najafzadeh, Macit Ilkit
Förderung
- Elite Researcher Grant Committee
- Mashhad University of Medical Sciences
Zitieren
APA
Najafzadeh, M. J., Shaban, T., Zarrinfar, H., Sedaghat, A., Hosseinikargar, N., Berenji, F., Jalali, M., Lackner, M., James, J. E., Ilkit, M., & Lass-Flörl, C. (2024). COVID-19 associated candidemia: From a shift in fungal epidemiology to a rise in azole drug resistance. Medical Mycology. https://doi.org/10.1093/mmy/myae031
Vancouver
Najafzadeh MJ, Shaban T, Zarrinfar H, Sedaghat A, Hosseinikargar N, Berenji F, et al. COVID-19 associated candidemia: From a shift in fungal epidemiology to a rise in azole drug resistance. Medical Mycology. 2024. doi:10.1093/mmy/myae031
BibTeX
@article{Najafzadeh2024,
author = {Najafzadeh, Mohammad Javad and Shaban, Tahmineh and Zarrinfar, Hossein and Sedaghat, Alireza and Hosseinikargar, Neginsadat and Berenji, Fariba and Jalali, Mahsa and Lackner, Michaela and James, Jasper Elvin and Ilkit, Macit and Lass-Flörl, Cornelia},
title = {COVID-19 associated candidemia: From a shift in fungal epidemiology to a rise in azole drug resistance},
journal = {Medical Mycology},
year = {2024},
doi = {10.1093/mmy/myae031}
}
EUVIMED